Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-09-09

Clinical Trial Update: Combination Immunotherapy Targeting Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of a combination immunotherapy for melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Unnamed combination immunotherapy

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: RECRUITING